EXOMIND (BTL-699) for the Reduction of Food Cravings

NACompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

February 9, 2023

Primary Completion Date

June 20, 2023

Study Completion Date

June 20, 2023

Conditions
Food Cravings
Interventions
DEVICE

Treatment with BTL-699

Four to six transcranial magnetic stimulation treatments with the BTL-699 device will be delivered over the left dorsolateral prefrontal cortex, spaced 2 to 3 days apart. The intensity will be adjusted according to the subject's feedback, up to 100% of the individual's motor threshold.

Trial Locations (1)

250 67

National Institute for Mental Health, Klecany

All Listed Sponsors
lead

BTL Industries Ltd.

INDUSTRY